FDA denies approval of generic Lovenox

Novartis AG and biotechnology firm Momenta Pharmaceuticals' generic version of anti-clotting drug Lovenox has been rejected by the FDA due to concerns about the treatment's effect on the immune system. Momenta executives said they would work with the FDA to address their concerns.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA